Shatavari: Benefits, Evidence, Dosage & Safety

Q: Does shatavari help with menopause symptoms?

This is the bestsupported claim on the page, and the trials are recent enough to read in full. Randomized, placebocontrolled trials found that standardized shatavari root extracts (300–500 mg/day) significantly improved menopausal symptom scores and quality of life over 8–12 weeks versus placebo (Mahajan et al., 2025; J Dietary Suppl, 2026). A separate 24week trial tested 250 and 500 mg/day in postmenopausal women (PMC12070120). Small trials, proprietary extracts, short durations. Promising is the right word. Proven is not.

Q: How long does it take shatavari to work?

The trials give us a partial answer. In one 8week perimenopause trial, stress and vigor improvements were already significant at week 4 and persisted at week 8; a second 12week trial reported earlier onset of benefit versus placebo (Mahajan et al., 2025; J Dietary Suppl, 2026). Effects beyond 24 weeks are unstudied. I will not invent a timeline the trials never tested.

Q: What is the difference between shatavari and ashwagandha?

Both are Ayurvedic rasayanas. Shatavari's traditional role is the women's reproductive tonic; ashwagandha's role is different. One 24week trial tested both, alone and combined, for postmenopausal symptoms (PMC12070120). Different traditional roles, different trial literature. Do not treat them as interchangeable.

TL;DR

Shatavari is the tuberous root of Asparagus racemosus, Ayurveda's classic women's reproductive tonic. In 2025–2026 randomized trials, standardized root extracts (300–500 mg daily) reduced perimenopausal symptom scores over 8–12 weeks. Evidence for lactation and fertility remains preliminary. Promising for menopause symptoms. Early for everything else.

What it is

Shatavari is the dried tuberous root of Asparagus racemosus Willd., a climbing plant native to India in the Asparagaceae family. The Ayurvedic Pharmacopoeia of India identifies the drug's botanical origin as the tuberous root of A. racemosus (Hayes et al., J Nat Med, botanical-origin analysis).

The characteristic constituents: steroidal saponins (shatavarins), flavonoids, polysaccharides (Patibandla et al., 2024). Constituents are chemistry, not proof of effect. I mention them because the trials standardize to them. That will matter when we get to dosing.

Traditional use

In Ayurveda, shatavari is classified as a rasayana (rejuvenative) and is the foremost traditional tonic for women's reproductive health: used for menstrual irregularities, as a galactagogue to support lactation, and for menopausal complaints (Ayurvedic herbal medicines in female reproductive health, a literature review).

Those are traditional indications. What follows is what controlled human studies have actually tested, and I want you to notice how narrow the overlap is. Tradition claims a lot. Trials have checked a little.

What modern research says

Perimenopausal symptoms

The strongest human evidence is a 2025 randomized, double-blind, placebo-controlled trial. Eighty perimenopausal women, aged 40–55. Half received 300 mg/day of a standardized shatavari root extract (SRI-81); half received placebo. Eight weeks. The numbers: Total Menopause Rating Scale scores fell 42.6% from baseline on shatavari versus 5.5% on placebo. Perceived stress scores fell roughly 30% from baseline. Hot-flash scores fell 26% versus 7% with placebo. No adverse events were reported. Liver and kidney markers remained stable (Mahajan et al., Int J Womens Health 2025 (primary paper)).

A striking result. Now the limitations, because I read the methods section too. Single site. Eight weeks. And a proprietary extract (SRI-81, supplied by Ixoreal BioMed; the paper declares no grant funding and no conflicts of interest). Results may not generalize to generic shatavari powder. That last point is the one I would tattoo on every supplement label: the trial tested one company's extract, not the herb in the abstract.

A second randomized, double-blind, placebo-controlled trial (n=150, 12 weeks) reported significant improvements in menopausal symptom frequency and intensity scores and in menopause-specific quality of life versus placebo, again with no adverse events (J Dietary Suppl, 2026). Note this trial was industry-sponsored, which warrants the usual caution about sponsorship bias. Sponsored trials are not automatically wrong. They are automatically worth a second look.

Sexual wellness

A prospective, randomized, double-blind, three-arm, placebo-controlled trial evaluated a standardized shatavari root extract for women's sexual wellness. Shatavari alone improved Total FSFI and sexual-satisfaction scores versus placebo, while broader mood (POMS) improvements were reported mainly in the shatavari-plus-ashwagandha combination arm (Ademola et al., 2026). This is a single trial, and I am not going to let one trial carry more weight than it can hold.

Postmenopausal symptoms (combination trial)

A 24-week randomized, double-blind, placebo-controlled trial in postmenopausal women tested shatavari aqueous extract (250 mg and 500 mg/day), ashwagandha extract, and a combination. The shatavari arms showed dose-dependent decreases in menopause-specific quality-of-life scores versus placebo, along with improvements in bone-turnover and inflammatory markers (PMC12070120). Because the trial also tested a combination arm, shatavari-specific effects should be read from the shatavari-only arms, not the combination results. Read the arms, not the headline.

Lactation and fertility — preliminary

Shatavari's traditional reputation as a galactagogue is strong, but the clinical evidence is still emerging. A 2025 randomized trial on postpartum lactation has been reported (Ajgaonkar et al., J Obstet Gynaecol 2025;45(1):2564168 (primary paper); efficacy details await full-text verification. Early randomized trials in PCOS suggest possible reproductive-parameter effects, but the data are preliminary (PCOS RCT). For now, lactation and fertility benefits remain traditional use with emerging (not established) clinical support. Emerging is a word I use when I mean "do not act on this yet."

Dosage

Dosage appears here only because clinical trials specify it. These are research doses of specific standardized extracts, not a personal recommendation, and they are not interchangeable with generic shatavari powder:

300 mg/day of a standardized root extract (SRI-81, Ixoreal Biomed, >10% shatavarins) for 8 weeks: the perimenopause RCT regimen (Mahajan et al., 2025).
500 mg/day of a standardized root extract (Aspurus) for 12 weeks: the second perimenopause RCT regimen; note this trial was industry-sponsored (Waleria Healthtech Pvt. Ltd.) (J Dietary Suppl, 2026).
250–500 mg/day of standardized aqueous root extract for 24 weeks: the postmenopausal trial's shatavari-only arms (PMC12070120).

Traditional powder (churna) doses were not tested in these trials. The trial doses and the traditional powder are different materials. Talk to a qualified practitioner about form and dose.

Safety & contraindications

In the two perimenopause RCTs above (8 and 12 weeks), no adverse events were reported; liver and kidney function markers remained stable in the 8-week trial (Mahajan et al., 2025; J Dietary Suppl, 2026).
Longer-term human safety data are limited. Eight and twelve weeks is not years.
Pregnancy: despite traditional use in pregnancy-related contexts, controlled human safety data in pregnancy are lacking. Avoid unless a clinician advises otherwise.
As with any supplement, check interactions with hormone-sensitive conditions and prescription medicines with your clinician. Safety data overall remain limited. Talk to a clinician before use.

FAQs

Does shatavari help with menopause symptoms?

This is the best-supported claim on the page, and the trials are recent enough to read in full. Randomized, placebo-controlled trials found that standardized shatavari root extracts (300–500 mg/day) significantly improved menopausal symptom scores and quality of life over 8–12 weeks versus placebo (Mahajan et al., 2025; J Dietary Suppl, 2026). A separate 24-week trial tested 250 and 500 mg/day in postmenopausal women (PMC12070120). Small trials, proprietary extracts, short durations. Promising is the right word. Proven is not.

Does shatavari increase breast milk?

It is Ayurveda's classic galactagogue, and I will not pretend the tradition means nothing. But controlled human evidence is still emerging: a 2025 lactation RCT has been reported (primary paper); efficacy details await full-text verification. Consider this traditional use with preliminary (not established) clinical support. I would not advise anyone to rely on it yet.

Is shatavari safe during pregnancy?

Controlled human safety data in pregnancy are lacking. That sentence is the whole answer. Despite some traditional pregnancy-related uses, the safe course is to avoid shatavari in pregnancy unless a qualified clinician advises otherwise. Tradition is not a safety trial.

How long does it take shatavari to work?

The trials give us a partial answer. In one 8-week perimenopause trial, stress and vigor improvements were already significant at week 4 and persisted at week 8; a second 12-week trial reported earlier onset of benefit versus placebo (Mahajan et al., 2025; J Dietary Suppl, 2026). Effects beyond 24 weeks are unstudied. I will not invent a timeline the trials never tested.

What is the difference between shatavari and ashwagandha?

Both are Ayurvedic rasayanas. Shatavari's traditional role is the women's reproductive tonic; ashwagandha's role is different. One 24-week trial tested both, alone and combined, for postmenopausal symptoms (PMC12070120). Different traditional roles, different trial literature. Do not treat them as interchangeable.

Can men take shatavari?

The clinical trials to date have enrolled women, and no male-specific efficacy data were found in the peer-reviewed literature reviewed here. Traditional use centers on women's health. That is all I can honestly say: no data, not no effect.

Sources

The perimenopause evidence is Mahajan, Avad, and Langade's 2025 randomized, double-blind, placebo-controlled study of shatavari root extract (SRI-81), published in the International Journal of Women's Health (doi:10.2147/IJWH.S544267), and the 2026 industry-sponsored trial in the Journal of Dietary Supplements (abstract). The 24-week postmenopausal trial of shatavari and ashwagandha extracts is at PMC12070120. The sexual-wellness trial is Ademola et al., 2026 (PMC12912092); the PCOS trial is at PMC12971452; and the reported 2025 lactation trial is Ajgaonkar et al. in the Journal of Obstetrics and Gynaecology (doi:10.1080/01443615.2025.2564168).

The traditional-use background is the literature review "Ayurvedic Herbal Medicines" on female reproductive health (PMC10981444), which also covers the shatavarin, flavonoid, and polysaccharide constituents. The botanical-origin analysis is Hayes et al. in the Journal of Natural Medicines (springermedizin.de).

Disclaimer

This article is for educational purposes only and is not medical advice. Shatavari's human clinical evidence is limited to a handful of short randomized trials on menopausal symptoms using specific standardized extracts. Consult a qualified Ayurvedic practitioner or physician before use, especially if you are pregnant, nursing, taking medication, or managing a hormone-sensitive condition.